Alirocumab not checked
Regeneron · REGN727 · SAR236553
FollowEvery change as it happens, and a Monday email
Trials
4 active
10 in total · 4 in the EU
What this is
- How it works
- An antibody: a lab-made immune protein built to latch onto one target in the body.-mab: monoclonal antibodies WHO name stem
- Tested for
- Hypercholesterolemia
- Main trialPhase 2
- “This study is researching an experimental drug called alirocumab, referred to as "study drug". In the United States, alirocumab is approved for the treatment of hypercholesterolemia (high blood cholesterol levels). The aim of the study is to see how safe and effective alirocumab is when given weekly to adult participants who have hypercholesterolemia. The study is looking at several other research questions, including: * What side effects may happen from taking the study drug once a week * How much study drug is in the blood at different times”In the company’s words, NCT07477704 on ClinicalTrials.gov
- Other names
- Praluent · REGN727 · SAR236553
Other drugs for Hypercholesterolemia
- ObicetrapibNewAmsterdam Pharma · Phase 3
- Laroprovstat/rosuvastatinAstraZeneca · Phase 3
- LaroprovstatAstraZeneca · Phase 3
- FDC laroprovstat/RosuvastatinAstraZeneca · Phase 3
- EnlicitideMerck & Co. · Phase 3
- Bempedoic acid/ezetimibeDaiichi Sankyo · Phase 3
Coming up1
- 29 DecPhase 2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials10
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2Active, not recruiting | 29 Dec 2026 | A Study to See How Safe and Effective Alirocumab is When Given Weekly to Adult Participants Who Have Hypercholesterolemia | |
| Phase 4Completed | 5 Mar 2020 | Evaluating Effect of the Study Drug Praluent (Alirocumab) on Neurocognitive Function When Compared to Placebo | |
| Phase 4Terminated | 8 Apr 2020 | Long Term Safety Study of PRALUENT | |
| Phase 3Completed | 12 Apr 2019 | Safety, Tolerability, and Effect of Alirocumab in High Cardiovascular Risk Patients With Severe Hypercholesterolemia Not Adequately Controlled With Conventional Lipid-modifying Therapies (ODYSSEY APPRISE) | |
| Phase 3Completed | 27 Sep 2019 | Study in Participants With Homozygous Familial Hypercholesterolemia (HoFH) | |
| Phase 3Completed | 14 Jan 2021 | An Efficacy and Safety Study of Alirocumab in Children and Adolescents With Heterozygous Familial Hypercholesterolemia | |
| Phase 4Ended | not given | ACAV: EFFICACY AND SAFETY OF ALIROCUMAB TO PREVENT EARLY CARDIAC ALLOGRAFT VASCULOPATHY IN RECENT HEART TRANSPLANT RECIPIENTS | |
| Phase 3Authorised | not given | Comparison of inclisiran or alirocumab to standard therapy in pediatric heterozygous familial hypercholesterolemia (HeFH) – the head-to-head PICOLO-FH clinical trial | |
| Phase 4Authorised | not given | The relationship of cholesterol-lowering drugs with steroid HORMONEs, bile acids, muscle morphology, vitamin D, the immune system and related diseases such as depression and osteoporosis | |
| Phase 4Authorised | not given | Early LDL -cholesterol reduction in patients with acute coronary syndrome: a randomized clinical trial |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026